Skip to main content

Table 1 Clinical characteristics of patients with HIV who participated in a national survey to determine prevalence of HIV drug resistance in Papua New Guinea (July 2017–April 2018)

From: High prevalence of pre-treatment HIV drug resistance in Papua New Guinea: findings from the first nationally representative pre-treatment HIV drug resistance study

Characteristics

n

%

(95% CI)

Sex

337

 

100

Male

128

37.0

(33.0–41.3)

 Female

207

62.5

(57.9–66.8)

 Unknown

2

0.5

(0.1–2.3)

Mean age, years

31.0

(29.6–32.4)

ART status

337

100

 

 Naïve

268

79.1

(69.7–86.2)

 Previous exposure to ART

69

20.9

(13.8–30.0)

WHO clinical staginga

323

100

 

 I

64

19.8

 II

74

22.9

 III

172

51.3

 IV

13

4.0

CD4 cell countsa

236

100

 

 ≤ 250 cells/mm3

146

61.9

 > 250 cells/mm3

90

38.1

NNRTI-based first-line ART

312

100

 

 TDF-based

267

84.0

(63.1–94.2)

 AZT-based

43

15.4

(5.7–35.4)

 d4T-based

2

0.5

(0.1–3.5)

  1. CI confidence interval, ART antiretroviral therapy, WHO World Health Organization, NNRTI non-nucleoside reverse transcriptase inhibitors, TDF tenofovir, AZT zidovudine, d4T stavudine
  2. aPresented as un-weighted proportions rest of parameters with confidence intervals are study weighted proportions